دورية أكاديمية
أعرض في EDS

Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders-An Introduction to the OBERON Project.

التفاصيل البيبلوغرافية
العنوان: Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders-An Introduction to the OBERON Project.
المؤلفون: Audouze K; Inserm UMR S-1124, Université de Paris, 75006 Paris, France., Sarigiannis D; HERACLES Research Center on the Exposome and Health, Aristotle University of Thessaloniki, Center for Interdisciplinary Research and Innovation, 57001 Thessaloniki, Greece., Alonso-Magdalena P; Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández, 03202 Elche, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain., Brochot C; Institut National de l'Environnement Industriel et des Risques (INERIS), Unité Modèles pour l'Ecotoxicologie et la Toxicologie (METO), Parc ALATA BP2, 60550 Verneuil en Halatte, France., Casas M; ISGlobal, 08003 Barcelona, Spain.; Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain., Vrijheid M; ISGlobal, 08003 Barcelona, Spain.; Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain., Babin PJ; Department of Life and Health Sciences, University of Bordeaux, INSERM U1211, MRGM, F-33615 Pessac, France., Karakitsios S; Enve.X, 55133 Thessaloniki, Greece., Coumoul X; Inserm UMR S-1124, Université de Paris, 75006 Paris, France., Barouki R; Inserm UMR S-1124, Université de Paris, 75006 Paris, France.; Service de Biochimie métabolomique et protéomique, Hôpital Necker enfants malades, AP-HP, 75015 Paris, France.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2020 Apr 23; Vol. 21 (8). Date of Electronic Publication: 2020 Apr 23.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Regional Medical Programs*, Endocrine Disruptors/*adverse effects , Metabolic Diseases/*epidemiology , Metabolic Diseases/*etiology, Animals ; Biological Assay/methods ; Biomarkers ; Computational Biology/methods ; Disease Susceptibility ; Europe/epidemiology ; Humans ; Metabolic Diseases/diagnosis ; Metabolic Diseases/metabolism ; Risk Assessment ; Systems Biology/methods
مستخلص: Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect ED-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA). OBERON will combine (1) experimental methods (in vitro, e.g., using 2D and 3D human-derived cells and tissues, and in vivo, i.e., using zebrafish at different stages), (2) high throughput omics technologies, (3) epidemiology and human biomonitoring studies and (4) advanced computational models (in silico and systems biology) on functional endpoints related to metabolism. Such interdisciplinary framework will help in deciphering EDs based on a mechanistic understanding of toxicity by providing and making available more effective alternative test methods relevant for human health that are in line with regulatory needs. Data generated in OBERON will also allow the development of novel adverse outcome pathways (AOPs). The assays will be pre-validated in order to select the test systems that will show acceptable performance in terms of relevance for the second step of the validation process, i.e., the inter-laboratory validation as ring tests. Therefore, the aim of the OBERON project is to support the organization for economic co-operation and development (OECD) conceptual framework for testing and assessment of single and/or mixture of EDs by developing specific assays not covered by the current tests, and to propose an IATA for ED-related metabolic disorder detection, which will be submitted to the Joint Research Center (JRC) and OECD community.
References: Environ Health Perspect. 2014 Jun;122(6):535-44. (PMID: 24610234)
J Clin Endocrinol Metab. 2015 Apr;100(4):1245-55. (PMID: 25742516)
Prog Lipid Res. 2009 Mar;48(2):73-91. (PMID: 19049814)
Sci Rep. 2013;3:2712. (PMID: 24048418)
Environ Health Perspect. 2011 Jul;119(7):1034-41. (PMID: 21367690)
Toxicol Sci. 2020 Jan 1;173(1):32-40. (PMID: 31596483)
Food Chem Toxicol. 2016 Jan;87:138-47. (PMID: 26683310)
Annu Rev Pathol. 2015;10:195-262. (PMID: 25621660)
Epidemiology. 2019 Sep;30(5):756-767. (PMID: 31373935)
Reprod Toxicol. 2008 Jan;25(1):136-8. (PMID: 18093799)
Methods Mol Biol. 2016;1451:3-16. (PMID: 27464797)
Reprod Toxicol. 2017 Mar;68:3-33. (PMID: 27760374)
J Lipid Res. 2011 Sep;52(9):1765-72. (PMID: 21724975)
Bioinformatics. 2019 Dec 15;35(24):5391-5392. (PMID: 31329252)
J Clin Invest. 2011 Sep;121(9):3589-97. (PMID: 21865645)
PLoS Comput Biol. 2010 May 20;6(5):e1000788. (PMID: 20502671)
Environ Health Perspect. 2019 Apr;127(4):47005. (PMID: 30994381)
Environ Health Perspect. 2017 Sep 01;125(9):096001. (PMID: 28934726)
J Clin Endocrinol Metab. 2015 Apr;100(4):1278-88. (PMID: 25742518)
Toxicol Appl Pharmacol. 2019 Sep 15;379:114640. (PMID: 31251942)
Nat Rev Endocrinol. 2017 Mar;13(3):161-173. (PMID: 27857130)
J Steroid Biochem Mol Biol. 2011 Oct;127(1-2):4-8. (PMID: 21251979)
Sci Rep. 2018 Apr 13;8(1):5963. (PMID: 29654281)
Hum Exp Toxicol. 2009 Feb;28(2-3):139-41. (PMID: 19713381)
Annu Rev Public Health. 2017 Mar 20;38:279-294. (PMID: 28068484)
Curr Drug Targets. 2016;18(1):35-55. (PMID: 27280795)
Environ Health Perspect. 2016 Sep;124(9):1453-61. (PMID: 27152837)
Biochimie. 2005 Jan;87(1):125-8. (PMID: 15733747)
PLoS One. 2011;6(6):e20887. (PMID: 21701582)
ALTEX. 2019 Jan 20;36(3):353-362. (PMID: 30662994)
J Am Assoc Lab Anim Sci. 2015 Mar;54(2):198-208. (PMID: 25836967)
Methods Mol Biol. 2018;1683:383-393. (PMID: 29082504)
Arch Toxicol. 2017 Nov;91(11):3477-3505. (PMID: 29051992)
Regul Toxicol Pharmacol. 2014 Feb;68(1):119-39. (PMID: 24287156)
Nat Rev Endocrinol. 2017 Aug;13(8):445-457. (PMID: 28524171)
PLoS One. 2017 Jun 1;12(6):e0178833. (PMID: 28570659)
ALTEX. 2014;31(3):341-56. (PMID: 25061899)
ALTEX. 2020 Jan 21;37(2):287-299. (PMID: 31960936)
Int J Hyg Environ Health. 2016 Jul;219(4-5):331-42. (PMID: 27216159)
Birth Defects Res C Embryo Today. 2011 Mar;93(1):34-50. (PMID: 21425440)
Int J Environ Res Public Health. 2019 Oct 14;16(20):. (PMID: 31615055)
ALTEX. 2012;29(1):3-91. (PMID: 22307314)
Nat Med. 2013 May;19(5):557-66. (PMID: 23652116)
Arch Toxicol. 2011 May;85(5):367-485. (PMID: 21533817)
Toxicol Appl Pharmacol. 2016 Mar 1;294:32-42. (PMID: 26812627)
Int J Epidemiol. 2012 Aug;41(4):930-40. (PMID: 21471022)
Arch Toxicol. 2015 Jan;89(1):15-23. (PMID: 25433540)
J Chem Inf Model. 2018 Aug 27;58(8):1501-1517. (PMID: 29949360)
Environ Int. 2018 Dec;121(Pt 1):561-573. (PMID: 30300814)
J Mol Endocrinol. 2018 Jul 13;:. (PMID: 30006342)
Toxicol In Vitro. 2012 Dec;26(8):1278-85. (PMID: 22643240)
Cell Mol Life Sci. 2010 Apr;67(8):1219-37. (PMID: 20063036)
معلومات مُعتمدة: 825712 Horizon 2020 Framework Programme
فهرسة مساهمة: Keywords: adverse outcome pathways; computational systems toxicology; endocrine disruptors; integrative approach; metabolic disorders; metabolism; non-alcoholic fatty liver diseases; non-animal testing; obesity; predictive toxicology
المشرفين على المادة: 0 (Biomarkers)
0 (Endocrine Disruptors)
تواريخ الأحداث: Date Created: 20200429 Date Completed: 20210129 Latest Revision: 20210129
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7216143
DOI: 10.3390/ijms21082988
PMID: 32340264
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms21082988